ArticleJournal of hematology & oncology2025

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study.

Yaxiong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.